TPCW
KALV

TD Private Client Wealth’s KalVista Pharmaceuticals KALV Stock Holding History

TD Private Client Wealth’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18
Closed -$462 – 1231
2021
Q1 		$462 Buy
+18
New +$473 ﹤0.01% 1131

Other funds holding KALV

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TD Private Client Wealth's KALV Position: Q2 2021 in Review

TD Private Client Wealth sold out of KalVista Pharmaceuticals (KALV) in Q2 2021, closing a stake of 18 shares — an estimated $462 sold.

TD Private Client Wealth first reported a position in KALV in Q1 2021 and held it in 1 quarter. The position peaked at $462 in Q1 2021. 110 funds tracked by Wall St. Rank hold KALV as of Q2 2021.

  • TD Private Client Wealth reported no remaining KalVista Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • TD Private Client Wealth sold 18 KalVista Pharmaceuticals shares in Q2 2021, an estimated $462.
  • TD Private Client Wealth first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • TD Private Client Wealth's KalVista Pharmaceuticals position peaked at $462 in Q1 2021.
  • 110 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2021.

Based on TD Private Client Wealth's 13F filing for Q2 2021, filed 16 Aug 2024.